SI21352A - Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina - Google Patents
Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina Download PDFInfo
- Publication number
- SI21352A SI21352A SI200220009A SI200220009A SI21352A SI 21352 A SI21352 A SI 21352A SI 200220009 A SI200220009 A SI 200220009A SI 200220009 A SI200220009 A SI 200220009A SI 21352 A SI21352 A SI 21352A
- Authority
- SI
- Slovenia
- Prior art keywords
- polysaccharide
- vaccine
- conjugate
- sero
- meningitidis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26343501P | 2001-01-23 | 2001-01-23 | |
PCT/US2002/001963 WO2002058737A2 (en) | 2001-01-23 | 2002-01-22 | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
SI21352A true SI21352A (sl) | 2004-06-30 |
Family
ID=23001755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200220009A SI21352A (sl) | 2001-01-23 | 2002-01-22 | Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina |
Country Status (38)
Country | Link |
---|---|
US (9) | US8722062B2 (et) |
EP (3) | EP2332581B1 (et) |
JP (6) | JP2005504718A (et) |
KR (2) | KR100947757B1 (et) |
CN (1) | CN100556459C (et) |
AP (1) | AP1897A (et) |
AU (2) | AU2007216743A1 (et) |
BE (3) | BE2012C050I2 (et) |
BR (1) | BRPI0206672B8 (et) |
CA (1) | CA2435681C (et) |
CR (1) | CR7035A (et) |
CY (2) | CY1113072T1 (et) |
DK (2) | DK2332581T3 (et) |
EA (1) | EA006947B1 (et) |
EC (1) | ECSP034701A (et) |
ES (3) | ES2388848T3 (et) |
FR (3) | FR12C0072I2 (et) |
GE (1) | GEP20053691B (et) |
HR (1) | HRP20030598B1 (et) |
HU (2) | HU230490B1 (et) |
IL (3) | IL157060A0 (et) |
IS (1) | IS6881A (et) |
LT (1) | LT5177B (et) |
LU (1) | LU92108I2 (et) |
LV (1) | LV13128B (et) |
MX (2) | MXPA03006561A (et) |
NO (1) | NO20033816L (et) |
NZ (2) | NZ622900A (et) |
OA (1) | OA12590A (et) |
PL (1) | PL226184B1 (et) |
PT (2) | PT2332581E (et) |
RO (1) | RO122761B1 (et) |
SI (1) | SI21352A (et) |
TN (1) | TNSN03041A1 (et) |
UA (1) | UA92579C2 (et) |
WO (1) | WO2002058737A2 (et) |
YU (1) | YU66103A (et) |
ZA (1) | ZA200306176B (et) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
PL226184B1 (pl) | 2001-01-23 | 2017-06-30 | Aventis Pasteur | Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
AU2014218428B2 (en) * | 2001-06-20 | 2016-08-25 | Glaxosmithkline Biologicals Sa | Capsular polysaccharide solubilisation and combination vaccines |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
DE60328481D1 (de) * | 2002-05-14 | 2009-09-03 | Novartis Vaccines & Diagnostic | Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält |
GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
WO2004033623A2 (en) * | 2002-05-16 | 2004-04-22 | Aventis Pasteur, Inc. | Animal component free meningococcal polysaccharide fermentation and seedbank development |
AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
WO2004043489A1 (es) * | 2002-11-14 | 2004-05-27 | Instituto Finlay. Centro De Investigacion-Produccion De Vacunas Y Sueros. | Metodo de obtencion de vacunas conjugadas y composiciones vacunales que las contienen. |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CA2514328C (en) | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
US9296795B2 (en) * | 2003-03-07 | 2016-03-29 | Wyeth Holdings, Llc. | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
WO2005004909A2 (en) * | 2003-05-07 | 2005-01-20 | Aventis Pasteur, Inc. | Method of enhanced immunogenicity to meningococcal vaccination |
WO2005020964A1 (en) * | 2003-06-02 | 2005-03-10 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
MXPA05014171A (es) * | 2003-06-23 | 2007-02-21 | Sanofi Pasteur Inc | Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c. |
EP2851088A1 (en) * | 2003-06-23 | 2015-03-25 | Baxter International Inc. | Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof |
EP1961426B1 (en) | 2003-10-02 | 2011-04-27 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
GB0406013D0 (en) * | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
AU2011204789B2 (en) * | 2004-04-22 | 2013-07-11 | Glaxosmithkline Biologicals S.A. | Immunising against meningococcal serogroup Y using proteins |
GB0408978D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Meningococcal fermentation for preparing conjugate vaccines |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
SI1740217T1 (sl) | 2004-04-30 | 2011-10-28 | Novartis Ag | Konjugirano meningokokno cepljenje |
GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
KR20070101207A (ko) * | 2004-08-30 | 2007-10-16 | 사노피 파스퇴르 인크 | 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신 |
GB0419846D0 (en) * | 2004-09-07 | 2004-10-13 | Chiron Srl | Vaccine adjuvants for saccharides |
MX2007003292A (es) * | 2004-09-21 | 2007-09-07 | Sanofi Pasteur Inc | Conjugados y vacuna con proteinas de polisacarido derivadas meningococales multivalentes. |
GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
WO2006113528A2 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
CN103083657B (zh) | 2005-06-27 | 2016-06-08 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
EP1931380A2 (en) | 2005-09-01 | 2008-06-18 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Multiple vaccination including serogroup c meningococcus |
US20070065462A1 (en) * | 2005-09-21 | 2007-03-22 | Ryall Robert P | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
BRPI0708849B1 (pt) | 2006-03-17 | 2022-05-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para a preparação de conjugados imunogênicos multivalentes complexos, os referidos conjugados, e composições farmacêuticas |
GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
TR201807355T4 (tr) | 2006-03-22 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Meningokokkal konjugatlarla immünizasyon rejimleri. |
US8414899B2 (en) | 2006-04-11 | 2013-04-09 | Yeda Research And Development Co. Ltd. | Vaccines comprising multimeric HSP60 peptide carriers |
NZ581367A (en) | 2007-06-04 | 2012-05-25 | Novartis Ag | Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis |
BRPI0818545A2 (pt) | 2007-10-19 | 2017-07-04 | Novartis Ag | formulações de vacinais meningocócicas |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
CN102300585A (zh) | 2008-12-17 | 2011-12-28 | 诺华有限公司 | 包含血红蛋白受体的脑膜炎球菌疫苗 |
US8003112B2 (en) * | 2009-04-16 | 2011-08-23 | Howard University | Meningococcal and pneumococcal conjugate vaccine and method of using same |
JP5781542B2 (ja) * | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | E.coliキャリアタンパク質に結合体化した多糖免疫原 |
JP2013522287A (ja) | 2010-03-18 | 2013-06-13 | ノバルティス アーゲー | 血清群b髄膜炎菌のためのアジュバント添加ワクチン |
FI3831406T3 (fi) | 2010-08-23 | 2024-08-06 | Wyeth Llc | Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita |
US9057716B2 (en) * | 2010-09-04 | 2015-06-16 | Novartis Ag | Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines |
ES2864635T3 (es) | 2010-09-10 | 2021-10-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
EP2655389A2 (en) | 2010-12-24 | 2013-10-30 | Novartis AG | Compounds |
CN103533954B (zh) | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | 含较低剂量的抗原和/或佐剂的联合疫苗 |
CN103764171B (zh) | 2011-07-08 | 2016-08-17 | 诺华股份有限公司 | 酪氨酸连接方法 |
WO2013068949A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
JP2015509963A (ja) | 2012-03-08 | 2015-04-02 | ノバルティス アーゲー | Tlr4アゴニストを含む混合ワクチン |
ES2750366T3 (es) | 2012-03-08 | 2020-03-25 | Glaxosmithkline Biologicals Sa | Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
WO2013132452A2 (en) | 2012-03-09 | 2013-09-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN102660602B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
MX2014014067A (es) | 2012-05-22 | 2015-02-04 | Novartis Ag | Conjugado de serogrupo x de meningococo. |
HUE041381T2 (hu) * | 2012-08-16 | 2019-05-28 | Pfizer | Glikokonjugációs eljárások és kompozíciók |
CA2882619A1 (en) | 2012-09-06 | 2014-03-13 | Novartis Ag | Combination vaccines with serogroup b meningococcus and d/t/p |
CN102861326A (zh) * | 2012-09-19 | 2013-01-09 | 天津康希诺生物技术有限公司 | 流脑多糖-蛋白质缀合疫苗及制备方法 |
JP2016502994A (ja) | 2012-12-18 | 2016-02-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ジフテリア及び/又は破傷風から防御するためのコンジュゲート |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
KR20150121265A (ko) * | 2013-03-18 | 2015-10-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 치료 방법 |
JP6739333B2 (ja) | 2013-07-11 | 2020-08-12 | ノバルティス アーゲー | 部位特異的化学酵素的タンパク質修飾 |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
ES2865485T3 (es) | 2014-05-24 | 2021-10-15 | Biological E Ltd | Nueva vacuna de conjugado meningocócico semisintético |
WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
EP3258850B1 (en) | 2015-02-20 | 2020-06-24 | Bayer HealthCare LLC | Contrast imaging agent with dissolved gas-evolving fluid |
KR20160011136A (ko) | 2015-03-25 | 2016-01-29 | 한국기계연구원 | 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법 |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
US11524115B2 (en) | 2015-12-30 | 2022-12-13 | Ascendis Pharma A/S | Auto injector with cartridge locking system |
KR102204927B1 (ko) | 2016-07-25 | 2021-01-19 | 에스케이바이오사이언스(주) | 피막 다당류-단백질 접합 백신의 품질 평가 방법 |
FI3506935T3 (fi) | 2016-09-02 | 2024-04-17 | Sanofi Pasteur Inc | Neisseria meningitidis -rokote |
EP3506933A2 (en) | 2016-09-02 | 2019-07-10 | GlaxoSmithKline Biologicals SA | Vaccines for neisseria gonorrhoeae |
PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
WO2019198096A1 (en) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Tetravalent meningococcal vaccine composition and process to prepare thereof |
EP3632465A1 (en) | 2018-10-03 | 2020-04-08 | Sanofi Pasteur Inc. | Combined immunization against meningococcal disease and human papillomavirus |
WO2020168146A1 (en) * | 2019-02-14 | 2020-08-20 | University Of Florida Research Foundation, Inc. | Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae |
CN110903388B (zh) * | 2019-12-03 | 2024-01-02 | 兰州生物制品研究所有限责任公司 | 一种将脑膜炎球菌抗血清去交叉反应的方法 |
EP3937983A4 (en) | 2019-12-17 | 2022-12-14 | 9286-3620 Québec Inc. | ORAL DELIVERY SYSTEMS BASED ON THE IN SITU FORMATION OF PROTEIN/POLYSACCHARIDE COACERVATES |
KR102610292B1 (ko) | 2021-02-10 | 2023-12-04 | 에스케이바이오사이언스(주) | 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법 |
WO2022178196A1 (en) | 2021-02-19 | 2022-08-25 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
WO2023200704A1 (en) | 2022-04-11 | 2023-10-19 | Sanofi Pasteur Inc. | Protein-saccharide conjugation with sodium cyanoborohydride |
WO2024030931A1 (en) | 2022-08-03 | 2024-02-08 | Sanofi Pasteur Inc. | Adjuvanted immunogenic composition against neisseria meningitidis b |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4351761A (en) | 1978-05-15 | 1982-09-28 | Research Corporation | Purified antigen to test for Neisseria gonorrhoeae antibodies |
US4404371A (en) | 1981-01-14 | 1983-09-13 | Battelle Memorial Institute | Carboxymethylcellulose with carbonate bridges and preparation thereof |
US4351762A (en) * | 1981-03-10 | 1982-09-28 | Bioresearch, Inc. | Rapid, quantitative peptide synthesis using mixed anhydrides |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4619828A (en) | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
DE3382433D1 (de) | 1982-11-10 | 1991-11-21 | Mitsubishi Heavy Ind Ltd | Nickel-chromlegierung. |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US4762713A (en) | 1983-07-05 | 1988-08-09 | The University Of Rochester | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers |
DE3660966D1 (en) | 1985-04-17 | 1988-11-24 | Akzo Nv | Method of applying a road marking composition |
DE3518706A1 (de) | 1985-05-24 | 1986-11-27 | Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe | Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften |
US4814276A (en) | 1986-04-25 | 1989-03-21 | Becton, Dickinson And Company | Selective medium for growth of neisseria |
ES2070312T5 (es) | 1988-12-19 | 2003-05-16 | American Cyanamid Co | Vacuna de proteina de membrana exterior meningococica de clase 1. |
US4963534A (en) | 1989-05-19 | 1990-10-16 | Merck & Co., Inc. | Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents |
NZ239643A (en) | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2101648C (en) | 1991-03-12 | 2003-09-09 | Rachel Schneerson | Polysaccharide-protein conjugates |
US5314811A (en) | 1992-07-13 | 1994-05-24 | Merck & Co., Inc. | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide |
WO1993004183A1 (en) | 1991-08-16 | 1993-03-04 | Merck & Co., Inc. | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide |
US5422427A (en) | 1991-09-17 | 1995-06-06 | The United States Of America As Represented By The United States Department Of Health And Human Services | Pneumococcal fimbrial protein A |
FR2682388B1 (fr) | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
SK280702B6 (sk) * | 1992-05-23 | 2000-06-12 | Smithkline Beecham Biologicals S. A. | Kombinovaný očkovací prostriedok obsahujúci povrch |
US5445817A (en) | 1992-08-21 | 1995-08-29 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines |
JP4097691B2 (ja) | 1992-08-31 | 2008-06-11 | バクスター、ヘルスケア、ソシエテ、アノニム | C群髄膜炎菌に対するワクチン |
US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
WO1996040242A1 (en) | 1995-06-07 | 1996-12-19 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein |
US20030157129A1 (en) | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
US20020054884A1 (en) | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
ATE433329T1 (de) | 1995-06-23 | 2009-06-15 | Glaxosmithkline Biolog Sa | Impfstoff bestehend aus auf aluminium-phosphat adsorbiertem, konjugiertem polysaccharid antigen |
US6248334B1 (en) | 1997-01-08 | 2001-06-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process |
AU722315B2 (en) | 1997-01-21 | 2000-07-27 | Pasteur Merieux Serums Et Vaccins | Polysaccharide-peptide conjugates |
US6891037B1 (en) | 1997-01-24 | 2005-05-10 | Schweiz. Serum- & Impfinstitut Bern | Method for the isolation of polysaccharides |
US6403306B1 (en) | 1997-04-09 | 2002-06-11 | Emory University | Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto |
DE69826851T2 (de) | 1997-04-24 | 2005-02-10 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen |
ES2293681T3 (es) | 1997-05-28 | 2008-03-16 | Novartis Vaccines And Diagnostics S.R.L. | Medio de cultivo con extracto de soja como fuente de aminoacidos pero sin complejos proteinicos de origen animal. |
JP2002506448A (ja) * | 1997-06-24 | 2002-02-26 | カイロン コーポレイション | 抗髄膜炎菌ワクチン組成物を使用して成体を免疫する方法 |
US5965714A (en) | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
US6248570B1 (en) | 1997-12-23 | 2001-06-19 | Baxter International, Inc. | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
DK1147117T3 (da) | 1999-02-01 | 2004-10-25 | Eisai Co Ltd | Immunologiske adjuvansforbindelser |
HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
EP2270172B1 (en) | 1999-05-19 | 2016-01-13 | GlaxoSmithKline Biologicals SA | Combination neisserial compositions |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
ES2307553T3 (es) | 1999-12-02 | 2008-12-01 | Novartis Vaccines And Diagnostics, Inc. | Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion. |
US6800455B2 (en) * | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
UA85853C2 (uk) | 2000-06-29 | 2009-03-10 | Глаксосмітклайн Байолоджікалз С.А. | Полівалентна імуногенна композиція |
PL226184B1 (pl) | 2001-01-23 | 2017-06-30 | Aventis Pasteur | Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
-
2002
- 2002-01-22 PL PL373710A patent/PL226184B1/pl unknown
- 2002-01-22 WO PCT/US2002/001963 patent/WO2002058737A2/en active Application Filing
- 2002-01-22 NZ NZ622900A patent/NZ622900A/en not_active IP Right Cessation
- 2002-01-22 ES ES02707551T patent/ES2388848T3/es not_active Expired - Lifetime
- 2002-01-22 EP EP10183565.0A patent/EP2332581B1/en not_active Expired - Lifetime
- 2002-01-22 KR KR1020097005020A patent/KR100947757B1/ko active IP Right Grant
- 2002-01-22 US US10/054,638 patent/US8722062B2/en not_active Expired - Lifetime
- 2002-01-22 DK DK10183565.0T patent/DK2332581T3/en active
- 2002-01-22 GE GE5258A patent/GEP20053691B/en unknown
- 2002-01-22 EP EP02707551A patent/EP1355673B1/en not_active Expired - Lifetime
- 2002-01-22 KR KR1020037009760A patent/KR100947751B1/ko active Protection Beyond IP Right Term
- 2002-01-22 MX MXPA03006561A patent/MXPA03006561A/es active IP Right Grant
- 2002-01-22 OA OA1200300181A patent/OA12590A/en unknown
- 2002-01-22 PT PT101835650T patent/PT2332581E/pt unknown
- 2002-01-22 EA EA200300827A patent/EA006947B1/ru not_active IP Right Cessation
- 2002-01-22 UA UA2003087937A patent/UA92579C2/ru unknown
- 2002-01-22 CA CA2435681A patent/CA2435681C/en not_active Expired - Lifetime
- 2002-01-22 AP APAP/P/2003/002829A patent/AP1897A/en active
- 2002-01-22 YU YU66103A patent/YU66103A/sh unknown
- 2002-01-22 DK DK02707551.4T patent/DK1355673T3/da active
- 2002-01-22 IL IL15706002A patent/IL157060A0/xx unknown
- 2002-01-22 SI SI200220009A patent/SI21352A/sl not_active IP Right Cessation
- 2002-01-22 NZ NZ602682A patent/NZ602682A/en not_active IP Right Cessation
- 2002-01-22 RO ROA200300633A patent/RO122761B1/ro unknown
- 2002-01-22 JP JP2002559071A patent/JP2005504718A/ja active Pending
- 2002-01-22 HU HU0302999A patent/HU230490B1/hu active Protection Beyond IP Right Term
- 2002-01-22 ES ES15167027T patent/ES2892316T3/es not_active Expired - Lifetime
- 2002-01-22 BR BRPI0206672 patent/BRPI0206672B8/pt not_active IP Right Cessation
- 2002-01-22 PT PT02707551T patent/PT1355673E/pt unknown
- 2002-01-22 EP EP15167027.0A patent/EP2957300B1/en not_active Expired - Lifetime
- 2002-01-22 ES ES10183565.0T patent/ES2544979T3/es not_active Expired - Lifetime
- 2002-01-22 CN CNB028053982A patent/CN100556459C/zh not_active Expired - Lifetime
-
2003
- 2003-07-08 TN TNPCT/US2002/001963A patent/TNSN03041A1/en unknown
- 2003-07-22 IS IS6881A patent/IS6881A/is unknown
- 2003-07-22 IL IL157060A patent/IL157060A/en active IP Right Grant
- 2003-07-23 MX MX2014012844A patent/MX341760B/es unknown
- 2003-07-23 LT LT2003071A patent/LT5177B/lt not_active IP Right Cessation
- 2003-07-23 LV LVP-03-79A patent/LV13128B/lv unknown
- 2003-07-23 HR HRP20030598AA patent/HRP20030598B1/hr not_active IP Right Cessation
- 2003-07-23 CR CR7035A patent/CR7035A/es unknown
- 2003-07-23 EC EC2003004701A patent/ECSP034701A/es unknown
- 2003-08-08 ZA ZA200306176A patent/ZA200306176B/xx unknown
- 2003-08-27 NO NO20033816A patent/NO20033816L/no unknown
-
2007
- 2007-09-12 AU AU2007216743A patent/AU2007216743A1/en not_active Abandoned
-
2010
- 2010-09-03 AU AU2010219288A patent/AU2010219288A1/en not_active Withdrawn
-
2011
- 2011-04-14 JP JP2011089891A patent/JP5795721B2/ja not_active Expired - Lifetime
-
2012
- 2012-08-24 CY CY20121100766T patent/CY1113072T1/el unknown
- 2012-11-29 FR FR12C0072C patent/FR12C0072I2/fr active Active
- 2012-11-29 LU LU92108C patent/LU92108I2/fr unknown
- 2012-11-29 BE BE2012C050C patent/BE2012C050I2/fr unknown
- 2012-11-30 CY CY2012030C patent/CY2012030I2/el unknown
-
2013
- 2013-01-10 US US13/738,698 patent/US8741314B2/en not_active Expired - Lifetime
- 2013-03-15 US US13/842,976 patent/US20130224241A1/en not_active Abandoned
- 2013-03-15 US US13/843,037 patent/US8734813B2/en not_active Expired - Lifetime
- 2013-04-02 IL IL225522A patent/IL225522A/en active IP Right Grant
- 2013-12-13 JP JP2013257767A patent/JP2014043475A/ja active Pending
- 2013-12-13 JP JP2013257766A patent/JP2014043474A/ja active Pending
-
2014
- 2014-01-14 JP JP2014004347A patent/JP2014065745A/ja active Pending
- 2014-04-21 US US14/257,551 patent/US8999354B2/en not_active Expired - Fee Related
-
2015
- 2015-03-03 US US14/636,870 patent/US9173955B2/en not_active Expired - Fee Related
- 2015-09-16 US US14/855,994 patent/US9844601B2/en not_active Expired - Lifetime
- 2015-12-15 BE BE2015C077C patent/BE2015C077I2/fr unknown
- 2015-12-21 FR FR15C0094C patent/FR15C0094I2/fr active Active
-
2016
- 2016-04-15 JP JP2016081902A patent/JP2016128526A/ja active Pending
- 2016-10-14 HU HUS1600040C patent/HUS1600040I1/hu unknown
-
2017
- 2017-11-17 US US15/816,211 patent/US10143757B2/en not_active Expired - Fee Related
-
2018
- 2018-10-29 US US16/172,960 patent/US10617766B2/en not_active Expired - Fee Related
-
2022
- 2022-01-06 BE BE2022C502C patent/BE2022C502I2/fr unknown
- 2022-01-06 FR FR22C1001C patent/FR22C1001I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10617766B2 (en) | Multivalent meningococcal polysaccharide-protein conjugate vaccine | |
AU2014201676B2 (en) | Multivalent meningococcal polysaccharide-protein conjugate vaccine | |
AU2002241951A1 (en) | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
KO00 | Lapse of patent |
Effective date: 20120131 |